CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Bexagliflozindrug
Likely dose
Bexagliflozin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02820298
NCT02820298Phase 1Completed
CompareCT.gov

A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of A High-Fat Meal on the Pharmacokinetics of Bexagliflozin in Healthy Subjects

Theracos·interventional·Posted Jun 30, 2016·Updated Jun 10, 2021

In Brief

A Phase 1 clinical trial evaluating Bexagliflozin for Type 2 Diabetes Mellitus. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this study was to investigate the effect of a high-fat meal on the levels of bexagliflozin in the blood in healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 30, 2016
Enrollment StartJun 20, 2016
Primary CompletionAug 29, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.0 years ago

Interventions

Bexagliflozindrug

Bexagliflozin tablet, 20 mg